GREENVILLE, S.C., Jan. 29 /PRNewswire-FirstCall/ -- Signalife, Inc. announces that on January 25, 2007 it procured a $10 million revolving credit facility from SES Capital, LLC, under which Signalife may draw advances over a five year term to meet its cash flow requirements. All advances are repayable in a balloon payment on February 25, 2012, together with interest at 7% per annum. Signalife may, in its sole discretion, convert any principal and interest outstanding into common shares at a conversion rate equal to $3.15 per share or, if greater, the fair market value of those shares on AMEX as of the date of a draw request. As additional compensation for any conversion, Signalife will issue SES Capital a five-year warrant entitling it to purchase a number of common shares equal to 25% of the shares received upon conversion at the same price as the conversion price. Signalife also announces that its Marketing Agreement with Rubbermaid, Inc., under which Rubbermaid was granted the exclusive third-party right to market Signalife's Fidelity 100 heart monitor system, was terminated on January 24, 2007, and that Signalife has filed suit against Rubbermaid for its failure to perform under that agreement. Commenting on these events, Signalife's Chairman, Chief Executive Officer and President, Pamela M. Bunes, stated: "The credit line Signalife has procured will ensure we have sufficient funding to bring our products to market. Signalife is actively selling our Fidelity 100 heart monitors, and will continue to ramp up our sales efforts, including establishing relationships both internally and externally with sales and distribution partners." About Signalife, Inc. Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife, Inc. is the recipient of the Frost & Sullivan Technological Innovation Award for 2006. Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com/. More information concerning the events described in this release is contained in a form 8-K filed on this date by the company. Caution Regarding Forward-Looking Statements In this news release we make a number of statements, referred to as "forward-looking statements", which are intended to convey our expectations or predictions regarding the occurrence of possible future events or the existence of trends and factors that may impact our future plans and operating results, including statements relating to projected demand for our heart monitoring devices and increases in sales revenues. Any statements in this news release that are not statements of historical fact maybe considered to be forward-looking statements. These forward-looking statements are derived, in part, from various assumptions and analyses we have made in the context of our current business plan and information currently available to us and in light of our experience and perceptions of historical trends, current conditions and expected future developments and other factors we believe to be appropriate in the circumstances. You can generally identify forward-looking statements through words and phrases such as "seek," "anticipate," "believe," "estimate," "expect," "intend," "plan," "budget," "project," "may be," "may continue," "may likely result," and similar expressions. Each forward-looking statement should be read in context with, and with an understanding of, the various other disclosures concerning our company and our business made in this news release as well as other public reports we file with the SEC, as they may be amended. You should not place undue reliance on any forward-looking statement as a prediction of actual results or developments. We are not obligated to update or revise any forward-looking statement contained in this news release to reflect new events or circumstances unless and to the extent required by applicable law. DATASOURCE: Signalife, Inc. CONTACT: Pamela Bunes, President and Chief Executive Officer of Signalife, Inc., +1-864-233-2300, Web site: http://www.signalife.com/

Copyright